Additional file 1


Table S1

Table S2 Primers sequences for polymerase chain reactions
Gene / Primer Sequence
HPV6b E6 ( 471 bp)
Forward primer / 5’-AGATCTgccaccATGgaaagtgcaaatgcctc-3’
Reverse primer / 5’-GAATTCTTAGGGTAACATGTCTTCCATGCA-3’
HPV6b E7 ( 315 bp)
Forward primer / 5’-AGATCTgccaccATGcatggaagacatgttac-3’
Reverse primer / 5’-GAATTCTTAGGTCTTCGGTGCGCAGA-3’
HPV11 E6 ( 471 bp)
Forward primer / 5’-AGATCTgccaccATGgaaagtaaagatgcctc-3’
Reverse primer / 5’-GAATTCTTAGGGTAACAAGTCTTCCA-3’
HPV11 E7 ( 315 bp)
Forward primer / 5’-AGATCTgccaccATGcatggaagacttgttac-3’
Reverse primer / 5’-GAATTCTTATGGTTTTGGTGCGCAGA-3’
HPV16 E6 ( 483 bp)
Forward primer / 5’-AGATCTgccaccATGcaccaaaagagaactgc-3’
Reverse primer / 5’-GAATTCTTACAGCTGGGTTTCTCTACGTGT-3’
HPV16 E7 ( 303 bp)
Forward primer / 5’-AGATCTgccaccATGcatggagatacacctac-3’
Reverse primer / 5’-GAATTCTTATGGTTTCTGAGAACAGAT-3’
HPV18 E6 ( 483 bp)
Forward primer / 5’-AGATCTgccaccATGgcgcgctttgaggatcc-3’
Reverse primer / 5’-GAATTCTTATACTTGTGTTTCTCTGC-3’
HPV18 E7 ( 324 bp)
Forward primer / 5’-AGATCTgccaccATGcatggacctaaggcaac-3’
Reverse primer / 5’-GAATTCTTACTGCTGGGATGCACACC-3’


Figure S1 HPLC Fingerprint of SR-T100. A, Placebo; B, SR-T100 gel and C, Solamargine standard.

Figure S2 Apoptosis inhibition by Z-VAD-FMK significantly recovered cell viability in cells infected with low-risk type HPVs. a, b Lysates from HeLa cells that were treated with cisplatin (100 μM) in the presence or absence of the pan-caspase inhibitor Z-VAD-FMK (50 mM) for 24 h were immunoblotted with a cleaved caspase-3 antibody. a Caspase-3 cleavage was blocked in the presence of Z-VAD-FMK. b Caspase-3 activity was significantly decreased in the presence of Z-VAD-FMK compared with the cells without Z-VAD-FMK treatment. ***p <0.001. c Caspase-3 activity was analyzed in infected and SR-T100-treated cells that were incubated in the presence or absence of the pan-caspase inhibitor Z-VAD-FMK. Briefly, primary epithelial cells were cultured in 96-well plates and infected with different types of Lenti-HPVE6/E7 viruses. After 24 h, the infected cells were treated with Z-VAD-FMK for 30 min and then with SR-T100 (5 μg/ml) for 12 h. Caspase-3 activity was decreased in the presence of Z-VAD-FMK. **p <0.01 compared with the untreated group. d The viability of the infected and SR-T100-treated cells that were incubated in the presence or absence of the pan-caspase inhibitor Z-VAD-FMK was analyzed. Cell viability was determined using the CellTiter-Glo® luminescent cell viability assay. Briefly, the primary epithelial cells were cultured in 96-well plates and infected with different types of Lenti-HPVE6/E7 viruses. After 24 h, the infected cells were treated with Z-VAD-FMK for 30 min before they were treated with SR-T100 (5 μg/ml) for 12 h. Cell viability was determined. The data represent the mean ± SD from three independent experiments (*P<0.05).

Figure S1


Figure S2